Tag: big pharma

Deadly Weapon — The Mental Health Industry’s Lethal Treatments

Spencer Pearson, a former high school football star, was handed a life sentence last week for his 2023 violent and vicious stabbing attack of then 17-year-old Madison Schemitz in Ponte Vedra, Fla. It’s reported that Pearson “trembled and bowed his head in court” as the judge passed sentence.

Yes, as one would expect when one’s life is on the line, Pearson was contrite. And it’s important to note that Pearson’s attorney tried, unsuccessfully, to use the attackers “varied mental illnesses” as a mitigating defense. Of course, anyone would argue that someone who committed such a brutal attack must be suffering from mental illness. But is it that easy? Or is it possible that something else is at play?

For example, lots of young teenage boys’ experience getting dumped by girlfriends and don’t stalk them and then violently, repeatedly stab the former girlfriend, her mother and a stranger who stepped in to try and stop the rampage.

No. Something else is at play here and, based on other brutal attacks carried out by seemingly normal unassuming teenage boys, one cannot help but admit this attack has the odor of a life of mental health intervention.

Of course, it’s difficult to know for sure, but there are clues. According to one article in the Jacksonville Florida Times-Union “while in the third grade, a teacher made his parents aware that he suffered from anxiety.”

Did his parents act on that information and get their son mental health help to deal with his anxiety? Like so many other young boys, was third-grader Pearson “treated” with psychiatric mind-altering drugs at that time? That information has not been made public.

Keep reading

Weight-loss Drug Prescriptions for Kids and Teens Soar Despite No Safety Data

The number of weight-loss drug prescriptions provided by pediatric and adolescent medical specialists for children and teens increased sevenfold between October 2022 and September 2024, according to a MedPage Today analysis of Symphony, a prescription drug database.

Prescriptions for Novo Nordisk’s drugs liraglutide, the generic name for Saxenda, and semaglutide, the generic name for Wegovy and Ozempic, rose from 3,448 to 24,435 in the U.S. during that time.

Total prescriptions for all GLP-1 receptor agonist drugs — the broader class of drugs they are part of — prescribed by pediatric and adolescent medicine specialists, more than doubled during the same period, from 59,868 to 125,538.

However, those numbers do not even include GLP-1 drugs prescribed to children by primary care physicians or family medicine practitioners, or at compounding pharmacies, MedPage Today said.

Since the U.S. Food and Drug Administration (FDA) approved Wegovy in 2021, the drug — and the entire class of drugs — has become a sensation, promoted by influencers and celebrities, helping to fuel a massive new drug market estimated to be worth $100 billion a year for drugmakers.

About 20% of U.S. children and adolescents are chronically obese, according to the Centers for Disease Control and Prevention (CDC). The FDA approved Saxenda to treat obesity in kids 12 and up in December 2020 and Wegovy in December 2022.

Keep reading

Prozac: A Safe and Effective Treatment for Young People With Depression?

Could a commonly prescribed medication like Prozac be unsafe and ineffective for young people? According to a study published in the International Journal of Risk & Safety in Medicine, the answer is a clear yes.

This revelation challenges the widespread use of Prozac in treating adolescent depression and raises important questions about its safety and efficacy.

Prozac is one of the most frequently prescribed selective serotonin reuptake inhibitors (SSRIs) for adolescents struggling with depression.

However, the International Journal of Risk & Safety in Medicine study highlights significant safety concerns and questions the drug’s effectiveness in this vulnerable age group.

These findings suggest that what was once considered a standard treatment may not be as beneficial as previously thought.

Furthermore, regulatory data has highlighted inconsistencies in the reporting of adverse events, particularly suicidal behaviors, in clinical trials.

This underreporting distorts the true safety profile of Prozac, again indicating that the risks associated with the medication may be greater than the published studies suggest.

In light of these concerns, lifestyle changes and psychotherapy emerge as safer and more effective alternatives for treating adolescent depression.

Studies have shown that therapeutic approaches significantly reduce the risk of suicide among young patients. Understanding these alternatives is key for making informed decisions about mental health treatments for youth.

Keep reading

Harvard Study: Half of Adult Americans Eligible for Ozempic-Like Drugs

Glucagon-like peptide receptor agonists (GLP-1 RA) are the current financial rainmakers for BIG PHARMA.

Shi et al from Harvard reported recently in JAMA Cardiology.

Rapidly increasing uptake of semaglutide made it the top-selling drug in the US in 2023, with net sales of $13.8 billion. Quantifying the number of US adults eligible for semaglutide may guide future policies for this high-cost therapy and clarify potential implications for pharmaceutical spending.

The authors conclude that approximately 137 million adults or half the of the US population could have a clinical indication for once weekly GLP-1 RA drugs. This budget breaking conclusion no doubt will have to be addressed by the incoming HHS administration led by Robert F. Kennedy, Jr.

Keep reading

The bulk of credible science finds vaccines ‘can and do’ cause autism 

It’s amazing how many media figures remain so uninformed on the proven links between vaccine and autism. Without knowing the subject thoroughly, they keep falsely claiming the links have been “debunked.” 

Quite the opposite. 

I understand, because I was surprised, too, at what I learned when I was first assigned to cover the subject of vaccine safety at CBS News in 2001. At the time, I knew nothing about how vaccines work, scientific studies linking them to autism and many side other effects, or the medical and industry complex set up to defend them at any cost.

As an investigative reporter looking into this topic independently for more than two decades, I have helped expose a lot of what many are desperate to cover up. Some of my work on the topic has received journalism awards, and it has been cited favorably in the New England Journal of Medicine.

The news that’s been revealed in this time period, including compelling studies, testimony, court cases, and other evidence, is now easily accessible to any reporter who knows better than to simply google and get the industry and medical establishment approved narratives; or rely upon information from the vast network of groups, organizations, and fake “fact checkers,” ultimately set up by industry to spin us all.

With Donald Trump about to enter a second term in office, appointing and relying upon figures in public health who are familiar with the facts on these controversies (and willing to act upon them), we are already being exposed to incessant and increasingly desperate propaganda. 

The propagandists have important connections and plenty of money to spend to wield influence, as they long have, with federal agencies, members of Congress, and in media. They support fake “fact check” groups like Health Feedback and Science Feedback, dominate social media narratives, provide “journalism resources” that give false information, control medical information distributed by our once-esteemed public health agencies, influence medical associations, and back nonprofits that are designed to sound independent but put out industry misinformation. 

They have proven they will go to any lengths to protect their billion dollar profits and to try to stop any disruption of the corrupt medical establishment built to support them. 

Keep reading

First Needle-Free Patch RSV Vaccine Being Created

The U.S. National Institutes of Health (NIH) has granted the Biotech company Vaxxas Pty. Ltd. of Australia a worldwide license to a respiratory syncytial virus (RSV) antigen known as DS2. The license will allow for the firm to create the first needle-free and room-temperature stable RSV vaccine using a novel and “cutting edge” high-density microarray patch (HD-MAP). The DS2 antigen was developed at the NIH’s Vaccine Research Center and is designed to elicit a stronger and durable immune response than the currently approved DS-Cav1.1

Vaxxas’ HD-MAP technology is a needle-free vaccine consisting of thousands of tiny projections on a small patch. Each of the micro projections is coated with a dried vaccine formulation. The patch is applied to the skin then delivers the vaccine to immune cells located just beneath the skin’s surface.

The needle-free vaccine platform has gone through five Phase I clinical trials including a second-generation COVID-19 biologic candidate, as well as microarray versions of vaccines for influenza, measles, and rubella. Vaxxas plans to advance its HD-MAP RSV vaccine to a Phase I clinical study after completing preclinical development.1

Keep reading

DMSO has been proven to protect and heal the heart, lungs, liver, kidneys and prostate, and treat infertility

The therapeutic actions of DMSO, or dimethyl sulphoxide, make it well-suited to treat challenging conditions throughout the body, including many internal organs, such as the heart, liver, lungs, pancreas, kidneys and others.

DMSO has been proven to treat various diseases and conditions, including heart attacks, liver cirrhosis, gallstones, ARDS, lung damage from inhaling smoke, pulmonary fibrosis, pancreatitis, diabetes, nephritis, kidney stones, polycystic kidney disease, cystitis, epididymitis, genital pain, prostatitis, urethral syndrome, enlarged prostates, tubal infertility, endometrial inflammation and fibrosis.

In the article ‘How DMSO Protects and Heals the Internal Organs‘, A Midwestern Doctor (“AMD”) reviewed DMSO treatment protocols for conditions of our internal organs and provided general DMSO information for those looking to use it for their own health. 

The following is a summary of AMD’s article on protecting and healing our internal organs.  We encourage our readers to want to know more to refer to AMD’s article as in the summarising of it, details will get lost in translation. 

In a summary of another article in AMD’s DSMO series we previously published on strokes and neurological damage, we attached a PDF copy of AMD’s article because it is easier to search for specific terms in a PDF file.  We have done the same with this article, see the PDF below.

Keep reading

Cancer, Chemotherapy and Establishment Ignorance and Lies

The media (persuaded by the drug industry and the medical establishment which are, sadly, much the same thing) often seems to believe that chemotherapy is the only way to treat cancer. They may be rich and powerful but they’re wrong. The Guardian newspaper in the UK recently told their readers that “the damage to healthy tissues tends to be temporary” and “side effects usually disappear once the treatment is over.” If The Guardian studies the evidence in this book, they may like to reconsider that advice.

Information is the currency and capital for everything worthwhile we do. But there is more misinformation about cancer than just about anything else. Much of the misinformation is deliberate and corporate and there is more fraud, more confusion and more lying in this area of medicine than almost anywhere else. Charities, which supposedly exist to care for patients, are too often simply part of the cancer industry, beholden to the international pharmaceutical companies which make billions out of selling drugs which do little or no good and which are known to kill people. I don’t know of any cancer charity which doesn’t have links (usually financial) with big drug companies. This is, sadly, by no means unusual. When specific charities and patient associations were first formed, they were usually dedicated to caring and campaigning for patients but, sadly, charities and patient associations in all areas of medicine have been corrupted by the money which big drug companies have available for so-called marketing programmes. In the global cancer industry, the charities largely provide marketing and public relations services while the drug companies control the research that is done. When commercially inconvenient results are produced, they quickly suppress anything which might be financially damaging.

Cancer is not a single disease. It is a word which describes a great many quite different diseases. The one thing these diseases all have in common is that there is an uncontrolled and disorderly growth of abnormal cells. It is quite normal for cells to grow and to reproduce. Every minute, in every human body, an astonishing ten million cells divide. Usually, everything goes well. The cells divide in the right way and at the right time. But when a cell becomes a “cancer cell” it grows and divides at an abnormally rapid rate. These abnormal “cancer cells” destroy or push aside the normal, functioning cells. If the “cancer cells” are not stopped they may spread to other parts of the body and take up residence in other, different organs. “Cancer cells” may be carried around the body through the blood vessels or the lymph channels. When a cancer spreads and appears in another part of the body, the new growths are known as secondaries or metastases. Cancer can also spread by “crab-like” outgrowths (hence the name “cancer”).

Cancer is not the unknown, dark shrouded mystery killer that it is often thought to be. We do not know enough to recommend a lifestyle which will enable all individuals to avoid all cancers. But we know enough to make a difference. If we make the decision to avoid those factors which research has shown can lead to the development of cancer, and to do those things which can strengthen our defences against cancer, then I believe that we can dramatically influence our susceptibility to the disease and we can reduce the chances of a recurrence. We can’t stop it permanently but we can adjust the odds in our favour.

Keep reading

The U.S. Disease Epidemic and MAHA

Despite the huge amount of appropriated funds and the strenuous efforts of many individuals working in healthcare, Americans have increasingly suffered from a range of acute and chronic conditions over recent decades. As an influential member of the Trump administration, Robert F. Kennedy Jr. will have the opportunity to begin a reversal of this trend. He is developing plans to revamp the Federal agencies that regulate the medical and pharmaceutical industries.

Mr. Kennedy has presented incontrovertible data about the state of our health. He says the first step towards change is reforming policies and restoring compromised government oversight.   

It will take a concerted effort to convert a system that has allowed an array of degrading health conditions and an avalanche of human suffering. The statistics compiled by reliable scientific sources reveal details of this staggering crisis.

~ Six out of ten adults in America are living with a chronic illness. Seventy-four percent of American adults are overweight or obese. Rates of kidney disease and autoimmune conditions are going up. Cancer rates among young people are rising.

~ One-third of American teens are taking a prescription drug and nearly 30% are pre-diabetic. More than 18% of adolescents have nonalcoholic fatty liver disease. In 2020, 77% of young adults didn’t qualify for the military based on their health scores, forcing the military to lower its standards.

~ Health problems of young Americans begin at an early age even as they receive vaccines to protect them from illness. The CDC currently recommends at least 70 doses of 18 different vaccines from infancy until age eighteen, yet children have never had more acute and chronic ailments. These vaccination protocols urgently need re-evaluation.

The increasing use of prescription drugs by all Americans presents a dire warning. However, due to the unprecedented influence of lobbyists, elected representatives have allowed the pharmaceutical industry rampant freedom to sell questionable products.

Washington has not solved the problem of the revolving doors between Big Pharma and government regulators. This is the primary reason federal agencies are paralyzed by corporate interests and remain negligent in their protective roles. 

Keep reading

BlackRock Buys Blood-processing Facility, Pharmaceutical Lab as It Bets on Growing Profits in Healthcare

Global investment management firm BlackRock bought a blood-processing facility and a pharmaceutical lab in Australia as the first seed assets for its $1.5 billion Life Sciences investment platform, Financial Review reported.

The world’s largest asset manager partnered with Australian fund manager Wentworth Capital to make the purchase after the two firms determined that the life sciences real estate sector — including laboratories and research hubs — is a new asset class attractive to global investors and likely to be profitable.

Ben Hickey, head of Australian real estate for BlackRock, said the company thought that the sector is poised for long-term growth “driven by increased government and infrastructure spend[ing]” along with existing industry capabilities.

BlackRock launched the strategy after it surveyed European investors who invest in alternative asset strategies in September and found that a third of them were investing in life sciences real estate, the Financial Review reported.

Life sciences real estate, which refers to facilities built for medicine and healthcare, includes spaces for biotech, pharma and medical device companies. Examples include Merck’s recent expansion of its human papillomavirus or HPV vaccine production facility in Virginia, and Moderna’s new Innovation and Technology Centre for vaccine manufacture and mRNA research being constructed at an “unprecedented speed” near Oxford, England, in partnership with the U.K. government.

Hickey said Australia offered a high-growth low-risk market for the investment strategy and it was likely to see growth trends similar to what is happening in the European Union and the U.S., where rising industry demand is leading to the expansion of the life science and biomedical innovation hubs, according to the financial standard.

JLL, a different asset management company, forecasts in its 2024 report that worldwide pharma sales will be 80% higher by 2030 compared with 2023, driven largely by a doubling of revenue from “biologics.” Those include vaccines, gene therapies and monoclonal antibodies made from living cells that are altered through biotechnological methods. JLL predicts that growth will drive a recovery in the life sciences real estate market, which faltered in recent years.

However, as the number of biotech startups explodes, they are scrambling for new space, the report said, and demand for smaller life sciences spaces is already on the rise and should drive expansion of the market as a whole.

Anticipating this growth, BlackRock purchased two facilities owned by different investment funds previously managed by Charter Hall, an Australian property development and funds manager company, according to Financial Review.

The first is one of only four blood-processing facilities in Australia, operated by the Australian Red Cross Society under the name Lifeblood. BlackRock didn’t reveal what it paid for the 12,700-square-meter 24-hour facility in Alexandria, but Charter Hall paid $159 million for it in 2021.

The second is an 8,113-square-meter laboratory and office building in Macquarie Park currently rented by Israeli multinational Teva Pharmaceuticals, which is the world’s largest manufacturer of generic medicines. Charter Hall paid $53 million for the building in 2021.

BlackRock said it expects its new investments in life sciences to yield returns in line with its assets such as childcare facilities, which typically have a 4.5-5.5% rate of return.

Keep reading